Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1997 Jul;88(7):678-86.
doi: 10.1111/j.1349-7006.1997.tb00436.x.

Usefulness of a mouse myelin basic protein promoter for gene therapy of malignant glioma: myelin basic protein promoter is strongly active in human malignant glioma cells

Y Miyao  1 , K Shimizu, M Tamura, H Akita, K Ikeda, E Mabuchi, H Kishima, T Hayakawa, K Ikenaka
Affiliations

Usefulness of a mouse myelin basic protein promoter for gene therapy of malignant glioma: myelin basic protein promoter is strongly active in human malignant glioma cells

Y Miyao et al. Jpn J Cancer Res. 1997 Jul.

Abstract

We have searched for suitable promoters to regulate the expression of suicide genes for use in gene therapy. We have shown that the 1.3-kb fragment of the mouse myelin basic protein (MBP) promoter region initiates transcription in mouse glioma cells more efficiently than glial fibrillary acidic protein (GFAP) or myelin proteolipid protein (PLP) promoter. Among three different lengths of the MBP promoter, the shortest (256-bp) core promoter region initiates transcription as efficiently as 650-bp or 1.3-kb MBP promoter lengths in RSV-M glioma cells. To assess the suitability of the MBP promoter for use in clinical trials of malignant glioma gene therapy, we also had to show that it (the 1.3-kb length in this case) is effective in human glioma cells, as well as in murine glioma cells. The activity of the MBP promoter is much higher than that of GFAP or PLP promoter in most human glioma cells, suggesting that the MBP promoter would be best for directing toxic gene expression in gene therapy for patients with malignant glioma. Human glioma cells in which the MBP promoter was strongly active were sensitive to ganciclovir when they were transduced with MBP promoter/herpes simplex virus thymidine kinase gene-bearing retroviruses. In conclusion, retrovirus-targeted gene therapy for malignant glioma using this MBP promoter is a promising candidate for clinical trials.

PubMed Disclaimer

References

    1. ) Cone , R. and Mulligan , R. C.High efficiency gene transfer into mammalian cells: generation of helper‐free recombinant retrovirus with broad mammalian host range , Proc. Natl Acad. Sci. USA , 81 , 6349 – 6353 ( 1984. ). - PMC - PubMed
    1. ) Short , M. P. , Choi , B. C. , Lee , J. K. , Malick , A. , Breakfield , X. O. and Martuza , R. L.Gene delivery to glioma cells in rat brain by grafting of a retrovirus packaging cell line . J. Neurosci. Res. , 27 , 427 – 433 ( 1990. ). - PubMed
    1. ) Culver , K. W. , Ram , Z , Wallbridge , S. , Ishii , H. , Oldfleld , E. H. and Blaese , R. M.In vivo gene transfer with retro‐viral vector‐producer cells for treatment of experimental brain tumors . Science , 256 , 1550 – 1552 ( 1992. ). - PubMed
    1. ) Culver , K. W. , van Gilder , J. , Link , C. J. , Carlstorm , T. , Yuh , W. , Koch , K. , Doornbas , S. , Wetjen , B. and Blaese , R. M.Clinical protocol: gene therapy for the treatment of malignant brain tumors with in vivo tumor transduction with the herpes simplex thymidine kinase gene/ganciclovir system . Hum. Gene Ther. , 5 , 343 – 379 ( 1994. ). - PubMed
    1. ) Mikoshiba , K. , Okano , H. , Tamura , T. and Ikenaka , K.Structure and function of myelin protein genes . Annu. Rev. Neurosci. , 14 , 201 – 217 ( 1991. ). - PubMed

Publication types